Physician profile
Kristina Fortes
NPI 1063780260
$5,305.29
in general payments reported to CMS, 2019-2025
25 companies · $1,838 in 2025
The $1,838 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $926 · 2023: $1,570 · 2024: $972 · 2025: $1,838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,379.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $470.52 | 2022-2025 | Dojolvi |
| Abiomed | $407.70 | 2023-2025 | Impella |
| Abbvie INC. | $367.31 | 2022-2025 | |
| Glaxosmithkline, LLC. | $332.55 | 2025 | |
| Edwards Lifesciences Corporation | $305.61 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Astrazeneca Pharmaceuticals Lp | $252.16 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $251.62 | 2023-2025 | Austedo Xr, Uzedy |
| Acadia Pharmaceuticals INC | $250.58 | 2024-2025 | Nuplazid |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $245.17 | 2023-2024 | Jynarque |
| Argenx US, INC. | $241.46 | 2023-2024 | Vyvgart |
| Axsome Therapeutics, INC. | $241.20 | 2025 | Auvelity |
| Neurocrine Biosciences, INC. | $236.33 | 2024 | Ingrezza |
| Sage Therapeutics, LLC | $229.44 | 2023 | |
| Cvrx, INC. | $229.09 | 2022-2025 | Barostim Neo System |
| Gilead Sciences, INC. | $136.85 | 2025 | Yeztugo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $125.00 | 2023 | Valtoco |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.52 | 2023 | |
| Sk Life Science, INC. | $123.86 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $120.39 | 2023 | Rexulti |
| Novo Nordisk INC | $120.39 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $119.76 | 2022 | |
| Tactile Systems Technology INC | $107.06 | 2025 | Flexitouch Plus, Nimbl |
| Janssen Pharmaceuticals, INC | $104.00 | 2023 | Xarelto |
| Janssen Scientific Affairs, LLC | $85.12 | 2022 | |
| Abbott Laboratories | $77.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristina Fortes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.